התחל
ReutersReuters

Ryvu Therapeutics Signs Cooperation, Licence And Investment Deal With BioNTech

RVUBNTX

Ryvu Therapeutics SA RVU:

  • SIGNS RESEARCH COOPERATION DEAL, EXCLUSIVE LICENCE DEAL AND INVESTMENT DEAL WITH BIONTECH

  • PARTIES TO DEVELOP SMALL MOLECULE COMPOUNDS FOR THERAPY FOCUSED MAINLY ON IMMUNOLOGICAL MODULATION IN ONCOLOGY

  • REMUNERATION AT EUR 20.0 MILLION FOR GLOBAL, EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE A PORTFOLIO OF STAND-ALONE SMALL-MOLECULE STING AGONISTS

  • REMUNERATION ALSO FOR RIGHT TO OBTAIN EXCLUSIVE LICENSE FOR SEVERAL PROGRAMS WITHIN FRAMEWORK OF RESEARCH COOPERATION COVERING MANY THERAPEUTIC PURPOSES

  • ACCORDING TO LICENSE AGREEMENT, BIONTECH WILL FINANCE ALL RESEARCH AND DEVELOPMENT COSTS AS PART OF COOPERATION

  • COMPANY WILL BE ENTITLED TO GET PAYMENT OF UP TO EUR 876.2 MILLION FOR POTENTIAL MILESTONES

  • AMOUNT OF UP TO EUR 876.2 MILLION IS BIO-EURO VALUE

  • UNDER INVESTMENT AGREEMENT, BIONTECH TO INVEST FURTHER EUR 20.0 MILLION BY ACQUISITION OF NEW J-SERIES SHARES

  • BIONTECH TO HAVE PRIORITY RIGHT FOR NEGOTIATIONS ON ANY OF COMPANY'S ONCOLOGICAL MODULATION PROJECTS BEYOND SCOPE OF PARTNERSHIP DEAL

  • PRIORITY RIGHT TO RUN FOR FIVE YEARS FROM LICENCE DEAL OR TILL SELECTION OF BIONTECH EXCLUSIVE THERAPEUTIC GOALS

  • INITIAL PERIOD OF COOPERATION IS FIVE YEARS AND MAY BE EXTENDED

התחבר או צור חשבון בחינם לתמיד כדי לקרוא את החדשות האלה